Covid 19 Research using Clinical Trials (Home Page)
Report for D005759: Gastroenteritis NIH
(Synonyms: Gastroenteritis)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (10)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1590 | Newsfeed function Wiki | 0.71 |
| drug1650 | Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle） Wiki | 0.71 |
| drug1649 | Norovirus Bivalent (GI.1 / GII.4) Vaccine（low） Wiki | 0.71 |
| drug2024 | Random Donor Plasma Wiki | 0.71 |
| drug1648 | Norovirus Bivalent (GI.1 / GII.4) Vaccine（high） Wiki | 0.71 |
| drug987 | Gamification Wiki | 0.71 |
| drug151 | Aluminum adjuvant Wiki | 0.71 |
| drug652 | Convalescent Plasma Transfusion Wiki | 0.50 |
| drug2381 | Supportive Care Wiki | 0.41 |
| drug1645 | Normal saline Wiki | 0.32 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 A Randomized, Blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenulapolymorpha) in Healthy People Aged 6 Months to 59 Years
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
NCT04188691 Norwalk Gastroenteritis Norovirus Infections Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low） Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle） Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high） Biological: Normal saline Biological: Aluminum adjuvant MeSH:Caliciviridae Infections Gastroenteritis
Primary Outcomes
Measure: AE of local and systemic reactions within 30 minutes after each dose Time: 30 minutesDescription: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
Measure: All active AEs within 0-7 days after each dose Time: 7 daysDescription: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
Measure: All non-active collection AEs within 0-28（30） days after each dose Time: 28（30） daysMeasure: All SAEs within 6 months after the last dose is vaccinated Time: 6 months
Secondary Outcomes
Measure: Calculate geometric mean titer (GMT) of NoV GI.1 and GII.4 IgG antibodies Time: 28 days after the full vaccinationMeasure: Calculate positive rate of NoV GI.1 and GII.4 IgG antibodies Time: 28 days after the full vaccination
Measure: Calculate NoV GI.1 and GII.4 HBGA-blocking antibody titers Time: 28 days after the full vaccination
Measure: Calculate NoV GI.1 and GII.4 HBGA-blocking antibody positive rates Time: 28 days after the full vaccination
2 Innovative Tool to Limit Spread of SARS-CoV-2 in Residential Aged Care
This project is a randomised trial in order to determine if "gamification" can result in behaviour change for healthcare workers in the residential aged care setting. The app is for Age Care and care workers at the front line who are working to protect those most vulnerable to COVID-19. There are 2 groups in this trial on group will receive current and accurate information from an app. The other group will receives the app with the addition of a gamification competent, this will include rewarding experiences for staff doing safety behaviours and wellbeing behaviours. The purpose of the gamification is to create a calming and reassuring experience that injects positivity and joy where possible during this stressful time.
NCT04377165 COVID Influenza Gastroenteritis Behavioral: Gamification Behavioral: Newsfeed function MeSH:Gastroenteritis
Primary Outcomes
Description: Compare the number of sick leave prior to users utilising the app and at the end of the 4 weeks between the arms
Measure: To compare the hours of sick leave used over the course of the 4-week period post randomisation for each group Time: 4 weeksSecondary Outcomes
Description: Compare the amount of soap/sanitiser used between the arms
Measure: To compare handwashing behaviour Time: 4 weeksDescription: Compare the number of self tests between the two arms
Measure: To compare self-testing rates Time: 4 weeksDescription: Compare the amount of wipes/disinfectant used between the two arms
Measure: To compare the level of surface wipe down Time: 4 weeksDescription: Compare the number of COVID-19 tests between the two arms
Measure: To compare number of COVID-19 tests completed in Facilities Time: 4 weeksDescription: Compare the number of COVID-19 infections between the arms
Measure: To compare the number of COVID 19 infections in facilities Time: 4 weeksDescription: Compare the number of flu and gastroenteritis outbreaks between the arms
Measure: To compare the other types of outbreaks (Flu, gastroenteritis) Time: 4 weeksDescription: Compare the COVID 19 training between the two arms, this is via a self reported survey
Measure: To compare the awareness of COVID 19 training available to workers in the facilities Time: 4 weeksDescription: Compare the awareness of PPE training of the workers in the two arms, this is captured in self reported survey
Measure: To compare the awareness of PPE training available to workers in the facilities Time: 4 weeksDescription: Compare the amount of PPE used between the arms
Measure: To compare the levels of PPE material used in Time: 4 weeksDescription: Compare the wellbeing and self-efficacy between the two arms, this is captured in a self reported survey.
Measure: To compare the wellbeing and self-efficacy of the two groups Time: 4 weeks